Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 433.58M P/E - EPS this Y 1.70% Ern Qtrly Grth -
Income -66.86M Forward P/E -3.88 EPS next Y -19.70% 50D Avg Chg 20.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -9.00%
Dividend N/A Price/Book 1.39 EPS next 5Y - 52W High Chg -71.00%
Recommedations 3.00 Quick Ratio 29.44 Shares Outstanding 56.50M 52W Low Chg 58.00%
Insider Own 36.67% ROA -15.50% Shares Float 24.14M Beta 1.83
Inst Own 56.37% ROE -22.10% Shares Shorted/Prior 2.39M/2.14M Price 7.75
Gross Margin - Profit Margin - Avg. Volume 233,145 Target Price 4.67
Oper. Margin - Earnings Date May 7 Volume 267,862 Change 0.65%
About Design Therapeutics, Inc.

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

Design Therapeutics, Inc. News
03/27/24 Independent Director of Design Therapeutics Picks Up 88% More Stock
03/23/24 Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth
03/20/24 Design Therapeutics, Inc. (NASDAQ:DSGN) Q4 2023 Earnings Call Transcript
03/20/24 Q4 2023 Design Therapeutics Inc Earnings Call
03/19/24 Design Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial Results
03/12/24 Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio Update
12/18/23 Design Therapeutics, Inc. (DSGN) Upgraded to Buy: Here's What You Should Know
11/25/23 Positive Signs As Multiple Insiders Buy Design Therapeutics Stock
11/14/23 Design Therapeutics Inc (DSGN) Reports Q3 2023 Financials, Plans Strategic Update
11/13/23 Design Therapeutics Reports Third Quarter 2023 Financial Results and Plans for a Comprehensive Portfolio Update in Early 2024
08/15/23 Why Shares of Design Therapeutics Are Plummeting on Tuesday
08/15/23 Redfin upgraded, CSSE downgraded: Wall Street's top analyst calls
08/15/23 4 big analyst cuts: Urban Outfitters has 'limited' EPS upside, per Citi
08/14/23 Design Therapeutics Provides Pipeline Update and Reports Second Quarter 2023 Financial Results
08/14/23 Design Therapeutics Reports Initial Results from Phase 1 Multiple-Ascending Dose Study of DT-216 for the Treatment of Friedrich Ataxia
06/18/23 Pleasing Signs As A Number Of Insiders Buy Design Therapeutics Stock \
05/31/23 Design Therapeutics to Present at the 2023 Jefferies Healthcare Conference
05/09/23 Design Therapeutics Provides Pipeline Updates and Reports First Quarter 2023 Financial Results
05/08/23 We're Hopeful That Design Therapeutics (NASDAQ:DSGN) Will Use Its Cash Wisely
DSGN Chatroom

User Image jasko1 Posted - 04/22/24

$DSGN possible gap fill all the way at $7 $PMEC possible gap fill close to $3 LFG 📈🚀

User Image dojidad Posted - 04/17/24

$DSGN This is the thing. Breaking resistances and trading over all the moving averages is a groovy thing. The RSI resetting is a confirmation an uptrend might be happening. The 21-day SMA (orange line) trending above the 200-day (blue line) is a nice compliment to an uptrend. Can it fill the gap? I got an alert set 4.16, and if volume is there, a position might be imminent.

User Image VIPTrades009 Posted - 04/05/24

$CNTB: 1.19 to 2.46 $DSGN: 2.70 alert to 4+ $ALDX: 3.60 to 4.97 high so far... $VVPR: 5.22 mention to 9.90 $AVGO Puts lotto from .80 to 2.35

User Image VIPTrades009 Posted - 1 month ago

$DSGN 4+ so far…. gap fill is at 7+ lets see if it keep going….

User Image VIPTrades009 Posted - 1 month ago

$CNTB 2.46 high so far… all targets and more…. looking for another swing… will alert soon….. $DSGN all targets and more….

User Image VIPTrades009 Posted - 03/28/24

$DSGN all targets and more… $CNTB

User Image StockInvest_us Posted - 03/27/24

Signal alert: $DSGN - Overbought Trend Short (Overvalued) https://stockinvest.us/l/5y2lgzINHS

User Image kshonstocks Posted - 03/27/24

$DSGN good chart and 4.99/cash https://finance.yahoo.com/quote/DSGN/key-statistics

User Image Madebymirco Posted - 03/26/24

$OPK something may be a foot Everything I see is pricing up or down in an active market but this....even $DSGN finally

User Image davidbo Posted - 03/26/24

$DSGN insider's would have bought cheaper but for mandated quiet period,but once they could they did.Great bullish signal that they bought at higher prices.

User Image insiderbuyingselling Posted - 03/25/24

$DSGN new insider buying: 1300 shares. http://insiderbuyingselling.com/?t=DSGN

User Image insiderbuyingselling Posted - 03/25/24

$DSGN new insider buying: 26965 shares. http://insiderbuyingselling.com/?t=DSGN

User Image ALOSETE Posted - 03/25/24

$DSGN consolidation is over. Ready to resume the uptrend.

User Image ALOSETE Posted - 03/25/24

$DSGN reverse is inminent. Stay tuned

User Image dojidad Posted - 03/23/24

$DSGN that's a heck of a gap. Everything looks good. Increased volume, trading over the 200 (blue line). I like it. If it really wants to do something special, it has to recapture Fridays high. My alert is 4.01. I'll do my DD before that.

User Image Cubaz Posted - 03/23/24

@pctrader99 LOOK 👀 $DSGN LONG

User Image VIPTrades009 Posted - 03/22/24

$DSGN All targets and more…

User Image davidbo Posted - 03/21/24

$DSGN Insider buying, baker bros,tang ,Blackrock holding good positions. Trading at 50% cash value. Smart people running company. Going much higher.

User Image _StockTrader Posted - 03/20/24

Real-Time Stock Data $DSGN Price: 2.92 Volume: 257404 Market Cap: 162405808 PE Ratio: -2.1481483 Powered by: OZSC

User Image Stocksrunner Posted - 03/19/24

🔍 Dive into After-Hours Market Activity! 🚀 $HQY reporting earnings for Q4 ending Jan 31, 2024. 📊 $TSHA Expect volatility post-earnings report. 🎨 $DSGN: Design Holdings in focus. 🔄 $CYCC Cyclical stock with potential movement. Stay tuned for updates!

User Image SomethingNew Posted - 03/19/24

$DSGN am i early here? 🫡 took some starters earlier

User Image DonCorleone77 Posted - 03/19/24

$DSGN Design Therapeutics reports Q4 EPS (21c), consensus (31c) Reports cash, cash equivalents and marketable securities were $281.8M as of December 31, . Design expects its cash, cash equivalents and marketable securities as of December 31 to fund its planned operating expenses through the next five years. "At Design, our vision is to develop a portfolio of first or best-in-class small molecules capable of treating a host of degenerative diseases by working with a patient's natural genome to restore cellular health. In recent months we have undertaken important work to evaluate the scope of our GeneTAC(TM) platform, which we believe has the potential to deliver clinical proof-of-concept in up to four programs, subject to research and development results, under our current cash runway through the next five years," said Pratik Shah, Ph.D., chairperson and chief executive officer of Design Therapeutics....

User Image Stock_Titan Posted - 03/19/24

$DSGN Design Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial Results https://www.stocktitan.net/news/DSGN/design-therapeutics-outlines-progress-across-gene-tac-platform-and-zt6kbxywanic.html

User Image valorallure Posted - 03/18/24

$DSGN Portolfio update and earnings out tomorrow. Will be interesting to see what they say about pipeline.

User Image valorallure Posted - 03/18/24

$DSGN Over two years of cash burn and would still trade below cash.

User Image ToastUvTheTown Posted - 03/13/24

$STRO $SGMT $MX $QURE $DSGN just waiting to go higher.

User Image thelastmaven Posted - 03/12/24

$DSGN March 19 earnings

User Image Stock_Titan Posted - 03/12/24

$DSGN Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio Update https://www.stocktitan.net/news/DSGN/design-therapeutics-to-webcast-fourth-quarter-and-full-year-2023-70ietw6xe8u7.html

User Image VIPTrades009 Posted - 03/06/24

$NRXP stopped out on initial alert… but if anyone added on break of 55… not done yet IMHO… $DSGN

User Image VIPTrades009 Posted - 02/27/24

$DSGN keep going… people will find it…

Analyst Ratings
RBC Capital Sector Perform Mar 20, 24
Wedbush Neutral Mar 20, 24
RBC Capital Sector Perform Nov 14, 23
Wedbush Neutral Aug 15, 23
SVB Leerink Market Perform Aug 15, 23
RBC Capital Sector Perform Aug 15, 23
RBC Capital Outperform May 10, 23
Wedbush Outperform May 10, 23
Goldman Sachs Neutral May 4, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
LAPPE RODNEY W Director Director Sep 29 Buy 2.347 21,000 49,287 133,024 10/02/23
William Arsani Director Director Mar 30 Buy 20 700,000 14,000,000 700,000 09/06/23
Prasad Deepa Director Director Aug 29 Buy 2.3058 12,000 27,670 23,806 08/30/23
William Arsani Director Director Aug 28 Buy 2.3 2,235,000 5,140,500 3,000,000 08/30/23
Siffert Joao MD President and CEO President and CEO Dec 19 Buy 8.42 7,450 62,729 132,619 12/21/22
George Simeon Director Director Dec 16 Buy 8.35 900,000 7,515,000 6,526,476 12/20/22
SR One Capital Fund I Aggregat... 10% Owner 10% Owner Dec 16 Buy 8.35 900,000 7,515,000 6,526,476 12/20/22
LAPPE RODNEY W Director Director Dec 09 Buy 7.9617 15,000 119,426 112,024 12/12/22
William Arsani Director Director Mar 21 Buy 18.9872 25,000 474,680 2,797,501 03/22/22
Xu Stella Director Director Mar 18 Sell 19.25 590,880 11,374,440 4,129,950 03/22/22